Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Operations (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Cash from Operations for 12 consecutive years, with 15548000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 24.99% year-over-year to 15548000.0, compared with a TTM value of 72252000.0 through Sep 2025, up 18.16%, and an annual FY2024 reading of 86231000.0, down 53.89% over the prior year.
  • Cash from Operations was 15548000.0 for Q3 2025 at CytomX Therapeutics, up from 15753000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 9349000.0 in Q1 2023 and bottomed at 41313000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 22338368.42, with a median of 21963000.0 recorded in 2023.
  • Peak annual rise in Cash from Operations hit 122.63% in 2023, while the deepest fall reached 1476.67% in 2023.
  • Year by year, Cash from Operations stood at 31192000.0 in 2021, then skyrocketed by 95.53% to 1393000.0 in 2022, then tumbled by 1476.67% to 21963000.0 in 2023, then rose by 9.36% to 19908000.0 in 2024, then increased by 21.9% to 15548000.0 in 2025.
  • Business Quant data shows Cash from Operations for CTMX at 15548000.0 in Q3 2025, 15753000.0 in Q2 2025, and 21043000.0 in Q1 2025.